July 8, 2010 – Boston Scientific Corp. today announced enrollment of the first patient in its MultiSENSE clinical trial, which the company plans to use to develop a clinical alert identifying the early onset of worsening heart failure. The trial is designed to evaluate multiple physiologic sensors in the company’s Cognis cardiac resynchronization therapy defibrillators (CRT-Ds).

July 8, 2010 – The Canadian Nuclear Safety Commission (CNSC) announced this week it has authorized the reactivation of the National Research Universal (NRU) reactor in Chalk River, Ontario, Canada. It is estimated that NRU will resume medical isotope production by the end of July, after being shut down in 2009 for several repairs.

Pulmonary embolism (PE) is generally treated with blood thinners, but a more aggressive treatment may be required for massive PE in hemodynamically compromised patients, said Ali Amin, M.D., a vascular surgeon at The Read Hospital and Medical Center in Reading, Pa.

Percutaneous mechanical thrombectomy (PMT) devices are increasingly being used to remove clots from coronary and peripheral vessels. They offer a faster treatment option than using traditional systemic thrombolytic (lytic) or catheter-directed thrombolysis (CDT).

OSF HealthCare System, owned and operated by The Sisters of the Third Order of St. Francis, Peoria, Ill., is a seven-hospital enterprise serving 2.5 million patients throughout Illinois and Michigan.

Three companies made significant purchases and product introductions in May and June in efforts to gain a larger share of the interventional, cath lab device market.

Combining IVUS, Therapeutic Devices

July 7, 2010 – Medical imaging company NovaRad recently expanded its distributor network by adding NXC Imaging to serve facilities in Wisconsin, South Dakota, North Dakota and parts of Illinois, Montana and Michigan.

NXC Imaging will represent NovaRad’s products including:

July 7, 2010 – Vicor Technologies Inc. recently announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its PD2i algorithm and software. This would secure a claim for identifying, in conjunction with patient medical history and other tests, congestive heart failure patients at elevated risk of cardiac mortality.

July 6, 2010 – Maquet Cardiovascular LLC recently announced it will become the exclusive U.S. distributor of the InterGard family of vascular grafts. This will go into effect on Oct. 1, 2010, when its current distribution agreement with W.L. Gore & Associates expires.

July 6, 2010 – A new trial testing a new method of detecting ischemia in patients with coronary artery disease (CAD) has received its first patient enrollments. Cambridge Heart Inc.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now